Cefzlan DC Tablet is an advanced and highly effective antibiotic solution, combining the proven efficacy of two powerful molecules in a convenient extended-release formulation. Each tablet contains Cefixime (200mg) and Dicloxacillin (500mg). This synergistic combination provides a comprehensive, broad-spectrum attack against a wide range of bacterial pathogens. While Cefixime, a third-generation cephalosporin, excels against Gram-negative bacteria, Dicloxacillin, a penicillinase-resistant penicillin, specifically targets and neutralizes Gram-positive bacteria, including those that have developed resistance. This dual mechanism of action makes Cefzlan DC a superior choice for treating complex and mixed infections.
The antibiotic market in India is one of the most significant and stable segments of the pharmaceutical industry, driven by a continuous demand for effective solutions to combat bacterial infections and antibiotic resistance. The Cefixime and Dicloxacillin combination addresses this critical need by offering reliable efficacy across a wide range of conditions, from respiratory and urinary tract infections to skin and soft tissue infections. The extended-release (ER) formulation is a key market differentiator, improving patient compliance and ensuring stable drug levels for better therapeutic outcomes. This makes Cefzlan DC a high-turnover product with consistent demand.
We offer an unparalleled PCD Pharma Franchise opportunity for Cefzlan DC Tablet. By partnering with us, you gain access to a quality-assured product manufactured in a WHO-GMP certified facility. Our business model is designed for your success, featuring exclusive monopoly rights in your designated territory to eliminate competition. We provide comprehensive marketing support, including promotional materials, visual aids, and product training, to help you build a strong market presence. With our reliable supply chain and dedicated customer support, you can focus on building a profitable and sustainable business, supplying a much-needed, high-quality antibiotic to your market.